5 These benefits might come from several factors: Weight loss itself improves mood and self-esteem Reduced inflammation (which is linked to depression) Direct effects on GLP-1 receptors in the brain, which are present in areas involved in mood regulation Improved physical function and mobility Healthier eating habits developed while on the medication Evidence suggesting caution is needed However, pharmacovigilance studies (which analyse reports of side effects submitted to drug safety databases) have identified signals for psychiatric adverse events with GLP-1 medications, including semaglutide
This review integrates current evidence on how brain peptides contribute to AD pathophysiology, summarizes recent progress in peptide-based therapeutic strategies and delivery platforms, and critically examines the remaining barriers to clinical translation, including bloodbrain barrier penetration, metabolic stability, off-target effects, and the need for biomarker-guided patient stratification
In contrast, multiple rodent pulmonary hypertension models demonstrate that GLP-1 receptor agonists, including exendin-4 and liraglutide, reduce vascular remodelling, inflammation, and ventricular hypertrophy via endothelial nitric oxide signalling and suppression of endothelin-1 pathways [68,69,72,73]
[DOI] [PMC free article] [PubMed] [Google Scholar] 44.McDonagh M.S., Selph S., Ozpinar A., Foley C
Iucci begins with a central truth: excess weight is strongly linked to cardiovascular disease
In recent year, allulose annual market is about 10,000 metric tons, and its increasing every year
.jpg)
